Fast Five Quiz: Multiple Myeloma Management

Joshua Richter, MD; Emmanuel C. Besa, MD


January 11, 2022

Three-drug combinations have been shown to induce higher response rates and greater depth of response than two-drug combinations in patients with multiple myeloma. Three-drug combinations are more likely to generate a response, slow disease progression, and extend survival. Because of these benefits, triplet combinations are currently considered the standard therapeutic regimen. Patients who are not initially candidates for a three-drug regimen can receive a two-drug regimen and have the third drug added once their performance status improves.

There is currently no treatment that can prevent monoclonal gammopathy of undetermined significance from progressing into multiple myeloma. Blood tests may be performed to check for signs of progression.

Adjunctive therapies that may be used in multiple myeloma include plasmapheresis, erythropoietin-stimulating agents, corticosteroids, radiation therapy, and surgical intervention.

Learn more about multiple myeloma therapies and outcomes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.